Mongolia to cover medical costs for Hepatitis D patients
The Mongolian government has allocated funds to cover the medical expenses of hepatitis D patients in the country.
The implementation of this decision is scheduled to commence in 2025 under the state budget allocation.
Mongolia has the highest record of Hepatitis D patients, with current figures standing at 36.5 percent, the highest in the world.
According to the Mongolian National News Agency, over five percent of hepatitis B patients develop hepatitis D, a 'satellite' virus that is usually associated with hepatitis B.
The European Union and the Russian Federation have manufactured Bulevirtide, an antiviral medication used globally to stop the entry of the Hepatitis D virus into liver cells.
